Compare GEMI & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | EIKN |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.3M | 631.0M |
| IPO Year | 2025 | 2026 |
| Metric | GEMI | EIKN |
|---|---|---|
| Price | $4.30 | $10.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $8.31 | ★ $25.60 |
| AVG Volume (30 Days) | ★ 2.6M | 455.9K |
| Earning Date | 05-14-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $179,572,000.00 | N/A |
| Revenue This Year | $35.05 | N/A |
| Revenue Next Year | $39.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.31 | N/A |
| 52 Week Low | $3.39 | $7.90 |
| 52 Week High | $34.67 | $16.50 |
| Indicator | GEMI | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 53.99 |
| Support Level | $3.90 | $8.62 |
| Resistance Level | $5.06 | $13.85 |
| Average True Range (ATR) | 0.40 | 1.16 |
| MACD | 0.10 | 0.10 |
| Stochastic Oscillator | 76.71 | 34.23 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.